ProKidney(PROK) - 2024 Q2 - Quarterly Results

Exhibit 99.1 ProKidney Reports Business Updates and Second Quarter 2024 Financial Results • Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKD • Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials • Closed $140 million upsized underwritten public offering and concurrent registered direct offering • Ended the second quarter with$431.5 million in cash and cash equivalents and marketable securitie ...